Do you use modified FOLFIRINOX preferentially over gem/nab-paclitaxel for first line metastatic pancreatic cancer patients?
Patient characteristics would unarguably be a deciding factor, but outside of these how would you approach the situation?
Answer from: Medical Oncologist at Academic Institution
Over and beyond patient characteristics, I prioritize mfolfirinox in pancreatic ductal adenocarcinoma patients with (i) known somatic or germ line alterations in DNA Damage Repair genes and (ii) in patients with a high likelihood of such alterations based on clinical/family history (if somatic or ge...
Sign in or Register to read more
Answer from: Medical Oncologist at Community Practice
I have always used modified FOLFIRINOX in pancreatic cancer. If the patients is PS 2 or worse doses can be further reduced and increased with improved PS like the REDOS trial.There are many references as to the equal effectiveness of FOLFIRINOX at reduced doses to full unrealistic doses.I pers...
Medical Oncologist
We utilize modified folfirinox in all patients with PS 0-1, offer gemzar plus Abraxane for PS 2, and add cisplatin to gemzar plus Abraxane to all who are BRCA positive or “BRCA like.”